05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£23,908,942 |
Nicolas Loebel |
3,538,991 |
£541,305 |
Junaid Bajwa |
1,193,697 |
£182,581 |
Jean Duvall |
1,163,529 |
£177,967 |
Jean Charest |
353,356 |
£54,047 |
Simon Sinclair |
256,327 |
£39,206 |
Carolyn Cross |
119,258,222 |
£18,241,088 |
M&G Plc |
67,254,901 |
£10,286,943 |
hInsight-NX, LLC |
42,272,654 |
£6,465,795 |
Robert Cross |
37,772,652 |
£5,777,499 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,310,513 |
CRUX Asset Management |
9,298,090 |
£1,422,185 |
Chelverton Asset Management |
7,957,311 |
£1,217,107 |
14:56 |
26,534 @ 15.32p |
14:38 |
6,527 @ 15.32p |
12:53 |
48,142 @ 15.32p |
11:33 |
20,000 @ 15.33p |
10:59 |
250,000 @ 15.25p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research